Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours
Brief Summary: Bevacizumab (called also Avastin ®) is a medicine preventing the creation of new blood vessels (a process called "angiogenesis"). This can reduce blood flow of the tumor and then decreasing the contribution of nutriments and oxygen to the cancer cells and prevent the tumor from growing.

In various types of cancers, as lung, breast, colorectal and renal cancer, addition of the bevacizumab to chemotherapy allowed to improve the disease outcome. The bevacizumab already benefits from a marketing authorization (MMA) for these various types of cancers.

The bevacizumab has also obtained MMA for the treatment of the ovarian cancer in its most frequent histological form (ovarian carcinoma). Clinical trials conducted in this indication demonstrated the importance to pursue the treatment by bevacizumab after the chemotherapy is ended.

This anti-angiogenic medicine is thought to be of a potential interest in sex cords- stromal since this tumors are very well vascularized.

The ALIENOR study aims to explore the interest and the clinical benefit of associating bevacizumab to the paclitaxel in order to treat patients suffering from recurring sex cords- stromal tumor treated beforehand by platinum chemotherapy


Options:
A: Arm Label: Placebo + Carboplatin + Paclitaxel -> Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to Veliparib | Arm Label: Veliparib + Carboplatin + Paclitaxel -> Placebo; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to Veliparib | Arm Label: Veliparib + Carboplatin + Paclitaxel -> Veliparib; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: OTHER; Name: Placebo to Veliparib; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo
B: Arm Label: Arm I (closed to accrual 10/10/2008); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib Tosylate | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Sorafenib Tosylate | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm I (closed to accrual 10/10/2008), Arm II
C: Arm Label: Arm I (bevacizumab and everolimus); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Everolimus, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (bevacizumab and placebo); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (bevacizumab and everolimus), Arm II (bevacizumab and placebo) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Arm I (bevacizumab and everolimus) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (bevacizumab and everolimus), Arm II (bevacizumab and placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (bevacizumab and placebo)
D: Arm Label: A - Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B - Paclitaxel + Bevacizumab followed by Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A - Paclitaxel, B - Paclitaxel + Bevacizumab followed by Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): B - Paclitaxel + Bevacizumab followed by Bevacizumab

Answer: D